From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
Our Data Science and Innovation teams employ a variety of leading-edge AI/ML methodologies to deliver insights that help save patient days of therapy. The teams utilize a number of AI/ML models – including Random Forest Classification, XGBoost Classification, Kalman Filter, K-Nearest Neighbor, K-Means Clustering, and ARIMA Modeling.
Below are just some of the innovations we’ve developed.
We use a variety of data sets to predict the likelihood that patients who are referred for Specialty medication will not be able to initiate on therapy due to patient journey roadblocks such as their insurance company denying coverage.
We use a variety of data sets to predict the likelihood that patients who are already on therapy for Specialty medication will discontinue therapy before their next refill.
We employ disparate data sets to project future inventory demand for each channel and National Drug Code (NDC) combination.
We produce statistically significant lists of pharmacies for the Pharmacy Call Programs that allow for intelligent, focused, and efficient outreach to pharmacies, maximizing the investments in these programs.
We employee NDC and brand-level features–such as channel level sales distribution, therapeutic category, and WAC price–to determine similar NDCs/brands for various analytic projects.
Like innovation? Consider joining us.Check Out Our Career Openings
